MORE NEWS - The CEO of Actinium Pharmaceuticals (ATNM) is Buying Shares
Catie Powers-July 17, 2018, 5:30 PM EDTSHARE ON:
Today, the CEO of Actinium Pharmaceuticals (NYSE: ATNM), Sandesh Seth, bought shares of ATNM for $7,900.
This recent transaction increases Sandesh Seth’s holding in the company by 7.5% to a total of $113.4K.
See today’s analyst top recommended stocks >>
Currently, Actinium Pharmaceuticals has an average volume of 3.51M.
Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $4.25, reflecting a -82.0% downside. Starting in November 2015, ATNM received 45 Buy ratings in a row. Seven different firms, including B.Riley FBR and Canaccord Genuity, currently also have a Buy rating on the stock.
The insider sentiment on Actinium Pharmaceuticals has been positive according to 11 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Actinium Pharmaceuticals, Inc. engages in the development of targeted therapies for patients with cancers lacking effective treatment options. The firm’s proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells.
DISCLAIMER: MY POSTS ARE STRICTLY MY OPINION, AND ANY OPINION
PROVIDED DOES NOT CONSTITUTE A BUY,SELL, OR HOLD RECOMMENDATION OR DECISION.
.
Please feel free to respond to my Posts.
.
Make it and don't get fooled by others.
